Solas BioVentures
VC Fund
Chattanooga, United States
Solas BioVentures is a biotech and medical device and venture fund based in Tennessee that finances early stage investments.
- Total investments:
- 22
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Solas BioVentures invests in
Stages Solas BioVentures invests in
Countries Solas BioVentures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
David Adair
|
|||
4 more contacts available
Investment Focus
Industry
- Health Care 11 (50%)
- Biotechnology 9 (41%)
- Medical Device 9 (41%)
- Medical 8 (36%)
- Software 2 (9%)
Stage
- Series A 6 (27%)
- Series B 4 (18%)
- Series C 4 (18%)
- Funding Round 3 (14%)
- Seed 2 (9%)
Country
- United States 14 (64%)
- Canada 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
David Adair
Managing Partner
|
Managing Partner | Total investments: 9 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Aurenar
|
Aurenar develops neurotechnology focused on non-invasive neuromodulation to address inflammation in critically ill patients. The company designs an ear-worn device that delivers imperceptible stimulation to a nerve in the ear to engage the body’s natural control of systemic inflammation. Its technology is intended for use in intensive care units tohelp reduce life-threatening complications linked to inflammatory responses. Aurenar conducts clinical pilot studies and trials to evaluate patient outcomes, hospital length of stay, and cost of care. Its products are targeted to hospitals, clinicians, and health systems seeking device-based approaches to managing inflammation in ICU settings. | $5.7M / Seed / Jul 28, 2026 | |
Francis Medical
|
Francis Medical is a medical technology company developing therapeutic solutions to treat prostate, kidney, and bladder cancer. Francis Medical is developing a device for treating prostate cancer, the second most common cancer in American men, using a new platform to treat endourological cancers, water vapor technology. The thermal energy stored insterile water vapor is used to treat cancerous tissue via a simple transurethral procedure, potentially minimizing life-altering side effects. | $80M / Series C / Jan 07, 2025 | |
Vektor Medical
|
Headquartered in San Diego, Vektor Medical is on a mission to revolutionize arrhythmia care for millions affected by atrial fibrillation and other arrhythmias. Through its AI-based, non-invasive arrhythmia analysis technology, vMap, the company aims to improve cardiac ablation outcomes, optimize workflows, and increase procedural efficiency. | $25M / Series A / Feb 05, 2024 | |
Basking Biosciences
|
Basking Biosciences is a startup that’s developing a therapy to restore blood flow to the brain during ischemic stroke, preventing hemorrhage and long-term damage. | $55M / Series A / Jan 30, 2024 | |
Arrivo BioVentures LLC
|
Our expertise is drug development. Whether we are developing a reformulated product, a new chemical entity, or a biologic, the team at Arrivo BioVentures has expertise in identifying regulatory strategies to expedite the path to approval and the efficient implementation of the clinical programs themselves. We coordinate with the FDA (and otherregulatory bodies) early and often to gain agreement on the development programs for our products, minimizing surprises and speeding implementation. | $45.3M / Series B / Nov 29, 2023 | |
Dimension Inx
|
Dimension Inx focuses on creating advanced biomaterials and 3D-printed implants that fundamentally change human disease and debilitation. It specializes in the fields of additive manufacturing, 3D-printing, biomaterials, and manufacturing. It was founded in 2017 and headquartered in Chicago, Illinois. | $12M / Series A / Feb 01, 2023 | |
EirSystems
|
EirSystems is a medical software company making technologies with blockchain applications. The company was founded in 2018 and is based in Chattanooga, Tennessee. | Seed / Aug 08, 2022 | |
Stimdia Medical
|
Stimdia Medical develops a non-invasive lung pacing device that reduces the time required to get a patient off a ventilator, resulting in significant cost savings. | $16M / Series B / Jul 14, 2022 | |
Pathware
|
Pathware is creating hardware and software to simplify digital pathology workflows. The company's complete slide imaging and sample management system, Bioptic™, rapidly returns a biopsy quality determination in order to verify that a viable biopsy was collected with greater than 96% certainty.Pathware’s purpose is to develop beautiful andintuitive hardware and software to simplify these critical diagnostic workflows and enable pathologists to increase their efficiency without sacrificing the quality of care. | $7M / Series A / Apr 19, 2022 | |
Cryosa
|
CryOSA is a medical device company developing novel treatments for obstructive sleep apnea. | $21.5M / Series B / Sep 23, 2021 | |
| See all 22 investments → | |||
Co-Investors
Orlando Health Ventures
3 deals together
Rex Health Ventures
3 deals together
Alloy Ventures
2 deals together
Arboretum Ventures
2 deals together
Chain Reaction
2 deals together
Coloplast
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Solas BioVentures invest in?
Solas BioVentures invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series A and Series B stage. Most of the 22 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Solas BioVentures?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Solas BioVentures?
The team at Solas BioVentures includes David Adair (Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
